Alpha-1-adrenergic receptors in heart failure: The adaptive arm of the cardiac response to chronic catecholamine stimulation

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 4, 2014, Pages 291-301

  Jensen, Brian C ^a   O'Connell, Timothy D ^b   Simpson, Paul C ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1 adrenergic receptors; cardioprotection; heart; heart failure; hypertrophy; ischemic preconditioning

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; DOXAZOSIN; MOXONIDINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL (TOPIC); CORONARY ARTERY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; CLASSIFICATION; DRUG EFFECTS; GENETICS; HEART; KNOCKOUT MOUSE; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; CATECHOLAMINES; HEART; HEART FAILURE; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84898600941     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000032     Document Type: Review

References (182)

1. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123:255-278.
2. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747-1762.
3. Sakata Y, Hoit BD, Liggett SB, et al. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation. 1998;97:1488-1495.
4. Adams JW, Sakata Y, Davis MG, et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA. 1998;95:10140-10145.
5. Ponicke K, Vogelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation. 1998;97:744-751.
6. Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2011; 51:518-528.
7. Jensen BC, Swigart PM, De Marco T, et al. {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail. 2009;2:654-663.
8. O'Connell TD, Ishizaka S, Nakamura A, et al. The alpha1A/C-and alpha1B-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest. 2003;111: 1783-1791.
9. Jensen BC, Swigart PM, Laden ME, et al. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol. 2009;54:1137-1145.
10. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
11. Myagmar BE, Rodrigo MC, Swigart PM, et al. The alpha-1A adrenergic receptor subtype Is expressed in only a sub-population of ventricular myocytes (Abstract). Circulation. 2007;116:184.
12. Wright CD, Chen Q, Baye NL, et al. Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac my-ocytes. Circ Res. 2008;103:992-1000.
13. Wright CD, Wu SC, Dahl EF, et al. Nuclear localization drives alpha1-adrenergic receptor oligomerization and signaling in cardiac myocytes. Cell Signal. 2012;24:794-802.
14. Williams RS, Lefkowitz RJ. Alpha-adrenergic receptors in rat myocardium. Identification by binding of [3H]dihydroergocryptine. Circ Res. 1978;43:721-727.
15. Karliner JS, Barnes P, Hamilton CA, et al. alpha 1-Adrenergic receptors in guinea pig myocardium: identification by binding of a new radio-ligand, (3H)-prazosin. Biochem Biophys Res Commun. 1979;90:142-149.
16. Mukherjee A, Haghani Z, Brady J, et al. Differences in myocardial alpha-and beta-adrenergic receptor numbers in different species. Am J Physiol. 1983;245:H957-H961.
17. Steinfath M, Chen YY, Lavicky J, et al. Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br J Pharmacol. 1992;107: 185-188.
18. 1b-adrenergic receptor. Proc Natl Acad Sci USA. 1997;94:11589-11594.
19. Rokosh DG, Bailey BA, Stewart AF, et al. Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D. Biochem Biophys Res Commun. 1994;200:1177-1184.
20. Stewart AF, Rokosh DG, Bailey BA, et al. Cloning of the rat alpha 1C-adrenergic receptor from cardiac myocytes. alpha 1C, alpha 1B, and alpha 1D mRNAs are present in cardiac myocytes but not in cardiac fibroblasts. Circ Res. 1994;75:796-802.
21. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA. 2002;99:9474-9479.
22. Jensen BC, Swigart PM, Simpson PC. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmie-debergs Arch Pharmacol. 2009;379:409-412.
23. O'Connell TD, Rokosh DG, Simpson PC. Cloning and characterization of the mouse a1C/A-adrenergic receptor gene and analysis of an a1C promoter in cardiac myocytes: role of an MCAT element that binds transcriptional enhancer factor-1 (TEF-1). Mol Pharmacol. 2001;59: 1225-1234.
24. Marino TA, Cassidy M, Marino DR, et al. Norepinephrine-induced cardiac hypertrophy of the cat heart. Anat Rec. 1991;229:505-510.
25. Long CS, Hartogensis WE, Simpson PC. Beta-adrenergic stimulation of cardiac non-myocytes augments the growth-promoting activity of non-myocyte conditioned medium. J Mol Cell Cardiol. 1993;25:915-925.
26. Long CS, Henrich CJ, Simpson PC. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Regul. 1991;2: 1081-1095.
27. Turner NA, Porter KE, Smith WH, et al. Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res. 2003;57:784-792.
28. Vlahos CJ. Signaling pathways mediated by the beta(2)-adrenergic receptor in the fibroblast: a novel role for PI 3-kinase. J Mol Cell Cardiol. 2001;33:1049-1051.
29. Gray MO, Long CS, Kalinyak JE, et al. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res. 1998;40:352-363.
30. Kim NN, Villarreal FJ, Printz MP, et al. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am J Physiol. 1995;269(3 pt 1):E426-E437.
31. Modesti PA, Vanni S, Paniccia R, et al. Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. J Cardiovasc Pharmacol. 1999;34:333-339.
32. Vignon-Zellweger N, Heiden S, Miyauchi T, et al. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci. 2012;91:490-500.
33. MacCarthy PA, Grocott-Mason R, Prendergast BD, et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation. 2000;101:142-147.
34. Zhao XS, Pan W, Bekeredjian R, et al. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation. 2006;114: 830-837.
35. Gourine AV, Molosh AI, Poputnikov D, et al. Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfu-sion injury via the ET(A) receptor and the mitochondrial K(ATP) channel in the rat in vivo. Br J Pharmacol. 2005;144:331-337.
36. Buu NT, Hui R, Falardeau P. Norepinephrine in neonatal rat ventricular myocytes: association with the cell nucleus and binding to nuclear alpha 1-and beta-adrenergic receptors. J Mol Cell Cardiol. 1993;25:1037-1046.
37. Tadevosyan A, Maguy A, Villeneuve LR, et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem. 2010;285:22338-22349.
38. Vaniotis G, Del Duca D, Trieu P, et al. Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal. 2011;23: 89-98.
39. Boivin B, Chevalier D, Villeneuve LR, et al. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem. 2003;278:29153-29163.
40. Bossuyt J, Chang CW, Helmstadter K, et al. Spatiotemporally distinct protein kinase D activation in adult cardiomyocytes in response to phenylephrine and endothelin. J Biol Chem. 2011;286: 33390-33400.
41. Hodgson JM, Cohen MD, Szentpetery S, et al. Effects of regional alpha-and beta-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans. Circulation. 1989;79:797-809.
42. Lorenzoni R, Rosen SD, Camici PG. Effect of alpha 1-adrenoceptor blockade on resting and hyperemic myocardial blood flow in normal humans. Am J Physiol. 1996;271(4 Pt 2):H1302-H1306.
43. Baumgart D, Haude M, Gorge G, et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090-2097.
44. Kern MJ, Horowitz JD, Ganz P, et al. Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol. 1985;5:840-846.
45. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of cat-echolamines. Circulation. 1992;85:1390-1397.
46. Jensen BC, Swigart PM, Montgomery MD, et al. Functional alpha-1B adrenergic receptors on human epicardial coronary artery endo-thelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2010;382: 475-482.
47. Chalothorn D, McCune DF, Edelmann SE, et al. Differential cardiovascular regulatory activities of the alpha 1B-and alpha 1D-adrenoceptor subtypes. J Pharmacol Exp Ther. 2003;305:1045-1053.
48. Turnbull L, McCloskey DT, O'Connell TD, et al. Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR. Am J Physiol Heart Circ Physiol. 2003;284: H1104-H1109.
49. Bristow MR, Minobe WA, Raynolds MV, et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737-2745.
50. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol. 1999;84:94R-102R.
51. Bonow RO, Ganiats TG, Beam CT, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation. 2012;125:2382-2401.
52. Bohm M, Diet F, Feiler G, et al. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 1988;12:357-364.
53. Bristow MR, Minobe W, Rasmussen R, et al. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 1988;247:1039-1045.
54. Steinfath M, Danielsen W, von der Leyen H, et al. Reduced alpha 1-and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol. 1992;105:463-469.
55. Vago T, Bevilacqua M, Norbiato G, et al. Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res. 1989;64:474-481.
56. Rokosh DG, Stewart AF, Chang KC, et al. Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. J Biol Chem. 1996;271:5839-5843.
57. Scholz H, Eschenhagen T, Neumann J, et al. Receptor-mediated regulation of cardiac contractility: inotropic effects of alpha-adrenoceptor stimulation with phenylephrine and noradrenaline in failing human hearts. In: Endoh M, Morad M, Scholz H, et al, eds. Molecular and Cellular Mechanisms of Cardiovascular Regulation. Tokyo, Japan: Springer-Verlag; 1996:317-325.
58. Skomedal T, Borthne K, Aass H, et al. Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther. 1997;280:721-729.
59. Monto F, Oliver E, Vicente D, et al. Different expression of adreno-ceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables. Am J Physiol Heart Circ Physiol. 2012;303:H368-H376.
60. Simpson P. Lessons from knockouts: the alpha1-ARs. In: Perez DM, ed. The Adrenergic Receptors in the 21st Century. Totowa, New Jersey: Humana Press; 2006:207-240.
61. Muntz KH, Zhao M, Miller JC. Downregulation of myocardial beta-adrenergic receptors. Receptor subtype selectivity. Circ Res. 1994;74: 369-375.
62. Wolff AA, Hines DK, Karliner JS. Refined membrane preparations mask ischemic fall in myocardial beta-receptor density. Am J Physiol. 1989;257(3 pt 2):H1032-H1036.
63. Sjaastad I, Schiander I, Sjetnan A, et al. Increased contribution of alpha 1-vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand. 2003;177:449-458.
64. Aguero J, Almenar L, Monto F, et al. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J Card Fail. 2012;18: 53-61.
65. Vinge LE, Oie E, Andersson Y, et al. Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 2001;281: H2490-H2499.
66. Vinge LE, Andressen KW, Attramadal T, et al. Substrate specificities of g protein-coupled receptor kinase-2 and-3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol. 2007;72:582-591.
67. Rockman HA, Choi DJ, Rahman NU, et al. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA. 1996;93:9954-9959.
68. Eckhart AD, Duncan SJ, Penn RB, et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res. 2000;86:43-50.
69. Vinge LE, von Lueder TG, Aasum E, et al. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 Uncovers Distinct Functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem. 2008;283:10601-10610.
70. von Lueder TG, Gravning J, How OJ, et al. Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 attenuates cardiac dysfunction after chronic pressure overload. Am J Physiol Heart Circ Physiol. 2012;303:H66-H74.
71. Du XJ, Fang L, Gao XM, et al. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol. 2004;37:979-987.
72. ALLHAT CRG. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
73. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA. 2004;291:54-62.
74. Player MS, Gill JM, Fagan HB, et al. Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens (Greenwich). 2006;8:860-864.
75. Cohn JN. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction. Circulation. 1993; 87(6 suppl):VI1-VI4.
76. Dhaliwal AS, Habib G, Deswal A, et al. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol. 2009;104:270-275.
77. Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-1803.
78. Cohn JN, Pfeffer MA, Rouleau JL, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-667.
79. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004;110:1437-1442.
80. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288-11293.
81. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21-28.
82. O'Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmaco-genetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PLoS One. 2012;7:e44324.
83. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54:432-444.
84. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5:463-468.
85. Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52: 644-651.
86. Vecchione C, Fratta L, Rizzoni D, et al. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation. 2002;105: 1700-1707.
87. Rodrigo MC, Joho S, Swigart PM, et al. The alpha-1-B adrenergic receptor subtype is required for physiological cardiac hypertrophy in normal development (abstract). Circulation. 2005;112:123.
88. Daly CJ, Deighan C, McGee A, et al. A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics. 2002;9:85-91.
89. Hosoda C, Koshimizu TA, Tanoue A, et al. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol. 2005;67:912-922.
90. 1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002;109:765-775.
91. McCloskey DT, Turnbull L, Swigart P, et al. Abnormal myocardial contraction in alpha(1A)-and alpha(1B)-adrenoceptor double-knockout mice. J Mol Cell Cardiol. 2003;35:1207-1216.
92. O'Connell TD, Swigart PM, Rodrigo MC, et al. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest. 2006;116:1005-1015.
93. Huang Y, Wright CD, Kobayashi S, et al. GATA4 is a survival factor in adult cardiac myocytes but is not required for alpha1A-adrenergic receptor survival signaling. Am J Physiol Heart Circ Physiol. 2008; 295:H699-H707.
94. Huang Y, Wright CD, Merkwan CL, et al. An alpha1A-adrenergic- extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation. 2007;115:763-772.
95. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest. 1983;72:732-738.
96. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1-and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985;56: 884-894.
97. Clark WA, Rudnick SJ, Andersen LC, et al. Myosin heavy chain synthesis is independently regulated in hypertrophy and atrophy of isolated adult cardiac myocytes. J Biol Chem. 1994;269:25562-25569.
98. Clark WA, Rudnick SJ, LaPres JJ, et al. Regulation of hypertrophy and atrophy in cultured adult heart cells. Circ Res. 1993;73:1163-1176.
99. Fuller SJ, Gaitanaki CJ, Sugden PH. Effects of catecholamines on protein synthesis in cardiac myocytes and perfused hearts isolated from adult rats. Stimulation of translation is mediated through the alpha 1-adrenoceptor. Biochem J. 1990;266:727-736.
100. Ikeda U, Tsuruya Y, Yaginuma T. Alpha 1-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol. 1991;260(3 pt 2):H953-H956.
101. Simpson PC. Comments on "Load regulation of the properties of adult feline cardiocytes: the role of substrate adhesion" which appeared in Circ Res 58:692-705, 1986 (letter). Circ Res. 1988;62:864-866.
102. Volz A, Piper HM, Siegmund B, et al. Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol. 1991;23:161-173.
103. Knowlton KU, Baracchini E, Ross RS, et al. Co-regulation of the atrial natriuretic factor and cardiac myosin light chain-2 genes during alpha-adrenergic stimulation of neonatal rat ventricular cells. Identification of cis sequences within an embryonic and a constitutive contractile protein gene which mediate inducible expression. J Biol Chem. 1991;266: 7759-7768.
104. Lee HR, Henderson SA, Reynolds R, et al. Alpha 1-adrenergic stimulation of cardiac gene transcription in neonatal rat myocardial cells. Effects on myosin light chain-2 gene expression. J Biol Chem. 1988; 263:7352-7358.
105. Bishopric NH, Simpson PC, Ordahl CP. Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin Invest. 1987;80:1194-1199.
106. Long CS, Ordahl CP, Simpson PC. Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells. J Clin Invest. 1989;83:1078-1082.
107. Kariya K, Farrance IK, Simpson PC. Transcriptional enhancer factor-1 in cardiac myocytes interacts with an alpha 1-adrenergic-and beta-protein kinase C-inducible element in the rat beta-myosin heavy chain promoter. J Biol Chem. 1993;268:26658-26662.
108. Kariya K, Karns LR, Simpson PC. An enhancer core element mediates stimulation of the rat beta-myosin heavy chain promoter by an alpha 1-adrenergic agonist and activated beta-protein kinase C in hypertrophy of cardiac myocytes. J Biol Chem. 1994;269:3775-3782.
109. Waspe LE, Ordahl CP, Simpson PC. The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest. 1990;85: 1206-1214.
110. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10: 248-254.
111. Rohde S, Sabri A, Kamasamudran R, et al. The alpha(1)-adrenoceptor subtype-and protein kinase C isoform-dependence of norepinephrine's actions in cardiomyocytes. J Mol Cell Cardiol. 2000;32: 1193-1209.
112. Avkiran M, Rowland AJ, Cuello F, et al. Protein kinase d in the cardiovascular system: emerging roles in health and disease. Circ Res. 2008;102:157-163.
113. Harrison BC, Kim MS, van Rooij E, et al. Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol. 2006;26:3875-3888.
114. Li J, Kritzer MD, Michel JJ, et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res. 2013;112: 128-139.
115. Zhang Z, Liu R, Townsend PA, et al. p90(RSK)s mediate the activation of ribosomal RNA synthesis by the hypertrophic agonist phenylephrine in adult cardiomyocytes. J Mol Cell Cardiol. 2013;59:139-147.
116. Backs J, Song K, Bezprozvannaya S, et al. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116:1853-1864.
117. Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004;24:8374-8385.
118. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clin Exp Pharmacol Physiol. 2004;31:791-794.
119. Hewett TE, Grupp IL, Grupp G, et al. Alpha-skeletal actin is associated with increased contractility in the mouse heart. Circ Res. 1994; 74:740-746.
120. Lopez JE, Myagmar BE, Swigart PM, et al. Beta-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res. 2011;109:629-638.
121. Hoyer K, Krenz M, Robbins J, et al. Shifts in the myosin heavy chain isozymes in the mouse heart result in increased energy efficiency. J Mol Cell Cardiol. 2007;42:214-221.
122. King BD, Sack D, Kichuk MR, et al. Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension. 1987;9:582-590.
123. Laks MM, Morady F, Swan HJ. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest. 1973;64:75-78.
124. Patel MB, Stewart JM, Loud AV, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation. 1991;84:2091-2100.
125. Stewart JM, Patel MB, Wang J, et al. Chronic elevation of norepineph-rine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol. 1992;262(2 pt 2):H331-H339.
126. Skomedal T, Aass H, Osnes JB, et al. Demonstration of an alpha adrenoceptor-mediated inotropic effect of norepinephrine in human atria. J Pharmacol Exp Ther. 1985;233:441-446.
127. Aass H, Skomedal T, Osnes JB, et al. Noradrenaline evokes an alpha-adrenoceptor-mediated inotropic effect in human ventricular myocardium. Acta Pharmacol Toxicol (Copenh). 1986;58:88-90.
128. Bruckner R, Meyer W, Mugge A, et al. Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol. 1984;99:345-347.
129. Curiel R, Perez-Gonzalez J, Brito N, et al. Positive inotropic effects mediated by alpha 1 adrenoceptors in intact human subjects. J Cardi-ovasc Pharmacol. 1989;14:603-615.
130. Landzberg JS, Parker JD, Gauthier DF, et al. Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation. 1991;84:1608-1614.
131. Skomedal T, Aass H, Geiran O, et al. Differential effects of cocaine on the positive inotropic effect of noradrenaline mediated by alpha1-and beta-adrenoceptors in failing human myocardium. Eur J Pharmacol. 2001;419:223-230.
132. Endoh M, Shimizu T, Yanagisawa T. Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog. Br J Pharmacol. 1978;64:53-61.
133. Puceat M, Terzic A, Clement O, et al. Cardiac alpha 1-adrenoceptors mediate positive inotropy via myofibrillar sensitization. Trends Pharmacol Sci. 1992;13:263-265.
134. Terzic A, Puceat M, Clement O, et al. Alpha 1-adrenergic effects on intracellular pH and calcium and on myofilaments in single rat cardiac cells. J Physiol. 1992;447:275-292.
135. Chu C, Thai KV, Park KW, et al. Intraventricular and interventricular cellular heterogeneity of inotropic responses to alpha1-adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2013;304:H946-H953.
136. Hirano S, Kusakari Y, O-Uchi J, et al. Intracellular mechanism of the negative inotropic effect induced by alpha1-adrenoceptor stimulation in mouse myocardium. J Physiol Sci. 2006;56:297-304.
137. McCloskey DT, Rokosh DG, O'Connell TD, et al. Alpha(1)-adreno-ceptor subtypes mediate negative inotropy in myocardium from alpha (1A/C)-knockout and wild type mice. J Mol Cell Cardiol. 2002;34: 1007-1017.
138. Wang GY, Yeh CC, Jensen BC, et al. Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol. 2010;298:H913-H920.
139. Endoh M, Blinks JR. Actions of sympathomimetic amines on the Ca2+ transients and contractions of rabbit myocardium: reciprocal changes in myofibrillar responsiveness to Ca2+ mediated through alpha-and beta-adrenoceptors. Circ Res. 1988;62:247-265.
140. Mohl MC, Iismaa SE, Xiao XH, et al. Regulation of murine cardiac contractility by activation of alpha(1A)-adrenergic receptor-operated Ca(2+) entry. Cardiovasc Res. 2011;91:310-319.
141. O-Uchi J, Komukai K, Kusakari Y, et al. alpha1-adrenoceptor stimulation potentiates L-type Ca2+ current through Ca2+/calmodulin-dependent PK II (CaMKII) activation in rat ventricular myocytes. Proc Natl Acad Sci USA. 2005;102:9400-9405.
142. O-Uchi J, Sasaki H, Morimoto S, et al. Interaction of alpha1-adrenoceptor subtypes with different G proteins induces opposite effects on cardiac L-type Ca2+ channel. Circ Res. 2008;102:1378-1388.
143. Venema RC, Kuo JF. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. J Biol Chem. 1993; 268:2705-2711.
144. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest. 2005;115:565-571.
145. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-1334.
146. Iwai-Kanai E, Hasegawa K, Araki M, et al. alpha-and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation. 1999;100:305-311.
147. Zhu H, McElwee-Witmer S, Perrone M, et al. Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis. Cell Death Differ. 2000;7:773-784.
148. Aries A, Paradis P, Lefebvre C, et al. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA. 2004;101:6975-6980.
149. Valks DM, Cook SA, Pham FH, et al. Phenylephrine promotes phos-phorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1/2 and protein kinase A. J Mol Cell Cardiol. 2002; 34:749-763.
150. Liang Q, Wiese RJ, Bueno OF, et al. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1-and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 2001;21:7460-7469.
151. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res. 2003;92:725-731.
152. Chan T, Dash R, Simpson P. An alpha-1A-adrenergic receptor subtype agonist prevents cardiomyopathy without increasing blood pressure (abstract). Circulation. 2008;118:S533.
153. Dash R, Chung J, Chan T, et al. A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med. 2011;66: 1152-1162.
154. Banerjee A, Locke-Winter C, Rogers KB, et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res. 1993;73:656-670.
155. Mitchell MB, Meng X, Ao L, et al. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res. 1995;76:73-81.
156. Tejero-Taldo MI, Gursoy E, Zhao TC, et al. Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart. J Mol Cell Cardiol. 2002;34:185-195.
157. Kitakaze M, Hori M, Morioka T, et al. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. J Clin Invest. 1994; 93:2197-2205.
158. Kitakaze M, Hori M, Sato H, et al. Beneficial effects of alpha 1-adrenoceptor activity on myocardial stunning in dogs. Circ Res. 1991;68:1322-1339.
159. Kitakaze M, Hori M, Tamai J, et al. Alpha 1-adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res. 1987;60:631-639.
160. Kudej RK, Shen YT, Peppas AP, et al. Obligatory role of cardiac nerves and alpha1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs. Circ Res. 2006;99:1270-1276.
161. Bankwala Z, Hale SL, Kloner RA. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catechol-amines mimics ischemic preconditioning. Circulation. 1994;90: 1023-1028.
162. Rorabaugh BR, Ross SA, Gaivin RJ, et al. alpha1A-but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism. Cardiovasc Res. 2005; 65:436-445.
163. Zhao X, Park J, Ho D, et al. Cardiomyocyte overexpression of the alpha1A-adrenergic receptor in the rat phenocopies second but not first window preconditioning. Am J Physiol Heart Circ Physiol. 2012;302: H1614-H1624.
164. Meng X, Brown JM, Ao L, et al. Norepinephrine induces cardiac heat shock protein 70 and delayed cardioprotection in the rat through alpha 1
165. Node K, Kitakaze M, Sato H, et al. Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. Circulation. 1997;96:1257-1265.
166. Tsuchida A, Liu Y, Liu GS, et al. alpha 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res. 1994;75:576-585.
167. Karliner JS, Honbo N, Epstein CJ, et al. Neonatal mouse cardiac myocytes exhibit cardioprotection induced by hypoxic and phar-macologic preconditioning and by transgenic overexpression of human Cu/Zn superoxide dismutase. J Mol Cell Cardiol. 2000; 32:1779-1786.
168. Yamashita N, Nishida M, Hoshida S, et al. Alpha 1-adrenergic stimulation induces cardiac tolerance to hypoxia via induction and activation of Mn-SOD. Am J Physiol. 1996;271(4 pt 2):H1356-H1362.
169. Xiao RP, Avdonin P, Zhou YY, et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myo-cytes. Circ Res. 1999;84:43-52.
170. Evans BA, Broxton N, Merlin J, et al. Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. Mol Pharmacol. 2011;79:298-307.
171. Lin F, Owens WA, Chen S, et al. Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res. 2001;89:343-350.
172. Chaulet H, Lin F, Guo J, et al. Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol. 2006;40:540-552.
173. Du XJ, Gao XM, Kiriazis H, et al. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res. 2006;71:735-743.
174. Zuscik MJ, Chalothorn D, Hellard D, et al. Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. J Biol Chem. 2001;276:13738-13743.
175. Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA. 1994;91: 10109-10113.
176. Iaccarino G, Keys JR, Rapacciuolo A, et al. Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. J Am Coll Cardiol. 2001;38:534-540.
177. Ross SA, Rorabaugh BR, Chalothorn D, et al. The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model. Cardiovasc Res. 2003;60:598-607.
178. Akhter SA, Milano CA, Shotwell KF, et al. Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha 1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. J Biol Chem. 1997;272:21253-21259.
179. Grupp IL, Lorenz JN, Walsh RA, et al. Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol. 1998;275(4 pt 2):H1338-H1350.
180. Lemire I, Ducharme A, Tardif JC, et al. Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyop-athy. Am J Physiol Heart Circ Physiol. 2001;281:H931-H938.
181. Bristow MR, Feldman AM, Adams KF Jr, et al. Selective versus non-selective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail. 2003;9:444-453.
182. Zakir RM, Folefack A, Saric M, et al. The use of midodrine in patients with advanced heart failure. Congest Heart Fail. 2009;15:108-111.